Ligand id: 667

Name: icatibant

Immunopharmacology Comments
Although not approved for inflammation we have included icatibant in GtoImmuPdb as it was evaluated as a potential disease modifying agent in patients with osteoarthritis (OA) in Phase 2 clinical trial NCT00303056. However, development has not progressed, and no trial results appear to have been published. The rationale for testing a B2 receptor antagonist in OA is discussed in [5].
Immunopharmacology Disease
Disease X-Refs Comment References
Hereditary angioedema Disease Ontology: DOID:14735
OMIM: 106100, 610618
Approved drug for HAE.